The Novo Nordisk headquarters in Bagsvaerd, Denmark. Photo: Nichlas Pollier/Bloomberg
Reuters
The US Food and Drug Administration’s (FDA) approval of an oral version of Novo Nordisk’s weight-loss drug Wegovy could potentially expand access to millions of patients and give the Danish company a much-needed fillip in the red-hot market.
The first GLP-1 pill specifically for obesity, also branded as Wegovy, is a 25mg oral formulation of semaglutide, the active ingredient in the blockbuster injectable version.
source